Back to search results

Phase 1 Study of XmAb541 and XmAb808 for Advanced Ovarian Cancer

This study is testing two investigational drugs, XmAb541 and XmAb808, in combination for people with advanced solid tumors, specifically high-grade serous ovarian cancer. The main goal is to find out if these drugs are safe and well-tolerated, and to determine the best dose to use in future studies. Researchers will also look at how the drugs affect your tumor. You may be able to join if you are 18 or older, have ovarian cancer that has a specific marker called CLDN6+, and meet other health requirements. The current status of this study is unclear.

Study design
This is an interventional study with a planned enrollment of 90 participants. It is a Phase 1 study, meaning it's focused on safety and finding the right dose.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will monitor for side effects from Day 1 to 2 years, and for dose-limiting toxicities from Day 1 to Day 43.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07593092

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Xencor, Inc.
~90 participants
Updated 2026-08-13 on ClinicalTrials.gov
What's tested:XmAb541XmAb808

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events
Measured over Day 1 to 2 years
+1 more outcome measured

Conditions

Ovarian Cancer

Explore related trials

Ovarian High Grade Serous AdenocarcinomaCD276 wt Allele

Where it's being run

4 sites across 2 states
New York3
Texas1

Who to contact

541-02 Study Information
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years.
CLDN6+ tumor
Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin
Adequate Eastern Cooperative Oncology Group performance status
Life expectancy ≥ 3 months
Adequate organ function

Exclusion

Prior exposure to a CLDN6 targeting immune cell engager
Patients with treated brain metastases may participate, provided they are radiologically stable.
Active known or suspected autoimmune disease
Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug
Clinically significant cardiovascular, pulmonary or gastrointestinal disease
Active viral hepatitis B or hepatitis C

What this trial measures

  • Incidence of Adverse EventsDay 1 to 2 years
  • Incidence of dose-limiting toxicitiesDay 1 to Day 43